Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa

BioLineRx initiates Phase 1/2a trial of GLIX1 for glioblastoma following 2025 financial results

BioLineRx (NASDAQ:BLRX), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the initiation of a first-in-human Phase 1/2a clinical trial evaluating GLIX1 for the treatment of recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.

Leia mais: BioLineRx initiates Phase 1/2a trial of GLIX1 for glioblastoma following 2025 financial results
Grafa

CollPlant narrowed net loss in 2025 as AbbVie milestone drives revenue surge

CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing innovative technologies based on its proprietary plant-derived recombinant human collagen (rhCollagen), today reported financial results for the full year ended December 31, 2025.

Leia mais: CollPlant narrowed net loss in 2025 as AbbVie milestone drives revenue surge
Grafa

MetaVia reports 9.1% weight loss in Phase 1 trial as clinical pipeline advances

MetaVia (NASDAQ:MTVA), a clinical-stage biopharmaceutical company developing novel therapies for obesity and metabolic-associated steatohepatitis (MASH), today reported financial results for the full year ended December 31, 2025, and provided an update on its advancing clinical pipeline.

Leia mais: MetaVia reports 9.1% weight loss in Phase 1 trial as clinical pipeline advances
Grafa

Aptevo Therapeutics reports 86% clinical benefit rate for Mipletamig in frontline AML

Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biopharmaceutical company focused on developing novel bispecific and multispecific immunotherapies for cancer, today reported financial results for the year ended December 31, 2025, and provided a strategic business update.

Leia mais: Aptevo Therapeutics reports 86% clinical benefit rate for Mipletamig in frontline AML
Grafa

Cognition Therapeutics aligns with FDA on registrational path for lewy body dementia treatment

Cognition Therapeutics (NASDAQ:CGTX), a clinical-stage biopharmaceutical company developing next-generation therapies for neurodegenerative disorders, today reported financial results for the full year ended December 31, 2025, and provided a comprehensive update on its lead candidate, zervimesine (CT1812).

Leia mais: Cognition Therapeutics aligns with FDA on registrational path for lewy body dementia treatment